[Newly treated XXXX : a French observational study].

@entity1 @entity410 @entity1625 @entity1092 @entity302
AIMS: To assess the characteristic features of @entity302 @entity1 treated for the first time with oral anti- @entity302 treatments. @entity1 and methods. All outpatients (adults and @entity1 ), who consulted for @entity302 attacks and for whom an oral anti- @entity302 treatment was necessary, as a first time prescription, were enrolled consecutively in this study from April 2001 up to January 2003. Data were available from a structured questionnaire delivered to all participating neurologists. RESULTS: Two hundred sixty neurologists included 2220 @entity1 (1162 males, 1057 females with a mean age of 41 years (from 1 month to 96 years). Forty-one percent of these @entity1 were referred by a general practitioner and 22 percent by emergency departments. Four hundred and thirty-seven @entity1 (19.7 percent) had only experienced a single @entity410 at treatment initiation. @entity1 were classified according to @entity1625 (43.9 percent of @entity1 ), generalized @entity302 (46.4 percent of @entity1 ), or non-classified @entity302 (9.7 percent of @entity1 ). Sixty-six percent of @entity1 had a biological check-up. Ninety-three percent of @entity1 underwent an EEG and 80.7 per cent a CT scan or brain MRI. The high risk of recurrence was the main reason given by neurologists for instituting anti- @entity302 treatment. The reason for initiating treatment was syndromic diagnosis in 23.7 percent of @entity1 with multiple @entity410 . The most frequently prescribed drug was @entity1092 (58.2 percent of @entity1 ) chosen because of its practical use and broad anti- @entity302 spectrum. CONCLUSION: This study provides a considerable amount of epidemiological and clinical information with a special emphasis on @entity302 , diagnostic assessment and factors that influence the initiation of treatment or not.
